Deficiency of ECHS1 causes mitochondrial encephalopathy with cardiac involvement. by Haack, Tobias B et al.
RESEARCH ARTICLE
Deficiency of ECHS1 causes mitochondrial encephalopathy
with cardiac involvement
Tobias B. Haack1,2,a, Christopher B. Jackson3, Kei Murayama4, Laura S. Kremer1,2, Andre Schaller5,
Urania Kotzaeridou6, Maaike C. de Vries7, Gudrun Schottmann8, Saikat Santra9, Boriana B€uchner10,
Thomas Wieland1,2, Elisabeth Graf1,2, Peter Freisinger11, Sandra Eggimann3, Akira Ohtake12, Yasushi
Okazaki13,14, Masakazu Kohda13, Yoshihito Kishita14, Yoshimi Tokuzawa14, Sascha Sauer15, Yasin
Memari16, Anja Kolb-Kokocinski16, Richard Durbin16, Oswald Hasselmann17, Kirsten Cremer18,
Beate Albrecht19, Dagmar Wieczorek19, Hartmut Engels18, Dagmar Hahn3, Alexander M. Zink18,
Charlotte L. Alston20, Robert W. Taylor20, Richard J. Rodenburg7, Regina Trollmann21, Wolfgang
Sperl22, Tim M. Strom1,2, Georg F. Hoffmann6, Johannes A. Mayr22, Thomas Meitinger1,2,23,24,
Ramona Bolognini5, Markus Schuelke8, Jean-Marc Nuoffer3,a, Stefan K€olker6,a, Holger Prokisch1,2,a, &
Thomas Klopstock10,23,24,a
1Institute of Human Genetics, Technische Universit€at M€unchen, 81675, Munich, Germany
2Institute of Human Genetics, Helmholtz Zentrum M€unchen, German Research Center for Environmental Health, 85764, Neuherberg, Germany
3Institute of Clinical Chemistry and University Children’s Hospital, University of Bern, 3010, Bern, Switzerland
4Department of Metabolism, Chiba Children’s Hospital, Chiba, 266-0007, Japan
5Division of Human Genetics, Department of Pediatrics, University of Bern, 3010, Bern, Switzerland
6Divisions of Inherited Metabolic Disease and Neuropediatrics, Department of General Pediatrics, University Hospital Heidelberg, D-69120,
Heidelberg, Germany
7Department of Pediatrics, Nijmegen Center for Mitochondrial Disorders, Radboud University Center, 6525 GA, Nijmegen, The Netherlands
8Department of Neuropediatrics and NeuroCure Clinical Research Center, Charite Universit€atsmedizin Berlin, 13353, Berlin, Germany
9Department of Pediatrics, Birmingham Children’s Hospital, Birmingham, B4 6NH, United Kingdom
10Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-University, 80336, Munich, Germany
11Department of Pediatrics, Klinikum Reutlingen, 72764, Reutlingen, Germany
12Department of Pediatrics, Faculty of Medicine, Saitama Medical University, Saitama, 350-0495, Japan
13Division of Translational Research, Research Center for Genomic Medicine, Saitama Medical University, Saitama, 350-1241, Japan
14Division of Functional Genomics & Systems Medicine, Research Center for Genomic Medicine, Saitama Medical University, Saitama, 350-1241,
Japan
15Max-Planck-Institute for Molecular Genetics, Otto-Warburg Laboratory, 14195, Berlin, Germany
16Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, United Kingdom
17Department of Neuropediatrics, Children’s Hospital of Eastern Switzerland St.Gallen, 9006, St. Gallen, Switzerland
18Institute of Human Genetics, University of Bonn, 53127, Bonn, Germany
19Institut f€ur Humangenetik, Universit€atsklinikum Essen, Universit€at Duisburg-Essen, 45122, Essen, Germany
20Wellcome Trust Centre for Mitochondrial Research, Institute of Neuroscience, The Medical School, Newcastle University, Newcastle upon Tyne,
NE2 4HH, United Kingdom
21Department of Pediatrics, Friedrich-Alexander-University of Erlangen-N€urnberg, 91054, Erlangen, Germany
22Department of Pediatrics, Paracelsus Medical University Salzburg, 5020, Salzburg, Austria
23Munich Cluster for Systems Neurology (SyNergy), 80336, Munich, Germany
24DZNE – German Center for Neurodegenerative Diseases, 80336, Munich, Germany
Correspondence
Holger Prokisch, Institute of Human Genetics,
Technische Universit€at M€unchen, Klinikum
rechts der Isar, Trogerstr. 32, 81675 Munich,
Germany. Tel: +49 89 3197 2890; Fax: +49
89 3187 3297; E-mail: prokisch@helmholtz-
muenchen.de and Thomas Klopstock,
Department of Neurology, Friedrich-Baur-
Institute, University of Munich, Ziemssenstr.
1, 80336 Munich, Germany. Tel: +49-89-
4400-57400; Fax: +49-89-4400-57402; E-
mail: tklopsto@med.lmu.de
Abstract
Objective: Short-chain enoyl-CoA hydratase (ECHS1) is a multifunctional
mitochondrial matrix enzyme that is involved in the oxidation of fatty acids
and essential amino acids such as valine. Here, we describe the broad pheno-
typic spectrum and pathobiochemistry of individuals with autosomal-recessive
ECHS1 deficiency. Methods: Using exome sequencing, we identified ten unre-
lated individuals carrying compound heterozygous or homozygous mutations
in ECHS1. Functional investigations in patient-derived fibroblast cell lines
included immunoblotting, enzyme activity measurement, and a palmitate load-
ing assay. Results: Patients showed a heterogeneous phenotype with disease
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onset in the first year of life and course ranging from neonatal death to survival
into adulthood. The most prominent clinical features were encephalopathy (10/
10), deafness (9/9), epilepsy (6/9), optic atrophy (6/10), and cardiomyopathy
(4/10). Serum lactate was elevated and brain magnetic resonance imaging
showed white matter changes or a Leigh-like pattern resembling disorders of
mitochondrial energy metabolism. Analysis of patients’ fibroblast cell lines (6/
10) provided further evidence for the pathogenicity of the respective mutations
by showing reduced ECHS1 protein levels and reduced 2-enoyl-CoA hydratase
activity. While serum acylcarnitine profiles were largely normal, in vitro palmi-
tate loading of patient fibroblasts revealed increased butyrylcarnitine, unmask-
ing the functional defect in mitochondrial b-oxidation of short-chain fatty
acids. Urinary excretion of 2-methyl-2,3-dihydroxybutyrate – a potential deriva-
tive of acryloyl-CoA in the valine catabolic pathway – was significantly
increased, indicating impaired valine oxidation. Interpretation: In conclusion,
we define the phenotypic spectrum of a new syndrome caused by ECHS1 defi-
ciency. We speculate that both the b-oxidation defect and the block in L-valine
metabolism, with accumulation of toxic methacrylyl-CoA and acryloyl-CoA,
contribute to the disorder that may be amenable to metabolic treatment
approaches.
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Introduction
Short-chain enoyl-CoA hydratase (ECHS1, synonym:
crotonase, EC 4.2.1.17), encoded by ECHS1 (cytogenetic
location: 10q26.3; GenBank accession number:
NM_004092.3; OMIM*602292), is a mitochondrial matrix
enzyme that catalyzes the second step of the b-oxidation
spiral of fatty acids, that is, the hydration of chain-short-
ened a,b-unsaturated enoyl-CoA thioesters to produce
b-hydroxyacyl-CoA.1 For each turn of this spiral pathway,
one acetyl-CoA molecule is released and utilized for either
the formation of citrate (tricarboxylic acid [TCA] cycle) or
ketone bodies (ketogenesis). Decreased activity of mito-
chondrial b-oxidation of fatty acids thus decreases the for-
mation of important energy substrates. Decreased
formation of acetyl-CoA results in increased susceptibility
to energy deficiency during catabolic states and to the dys-
function of organs that particularly rely on fatty acids and
ketone bodies as their energy source (e.g., cardiac tissue).
In addition, decreased formation of acetyl-CoA, and hence
limited availability of acetate, hampers myelination
because acetate is required for cholesterol biosynthesis.
Moreover, decreased formation of acetyl-CoA may hamper
posttranslational acetylation of mitochondrial proteins, a
mechanism that is emerging as a critical regulator of mito-
chondrial function.2 Evidence is increasing that ECHS1
has a wide substrate specificity and thus also plays an
important role in amino acid catabolism, in particular of
valine, where it converts methacrylyl-CoA to (S)-3-hy-
droxyisobutyryl-CoA and acryloyl-CoA to 3-hydroxypro-
pionyl-CoA (Fig. 1), the fourth step of valine oxidation.3
Accumulation of toxic methacrylyl-CoA and acryloyl-CoA,
two highly reactive intermediates that spontaneously react
with sulfhydryl groups of, for example, cysteine and
cysteamine, is suspected to cause brain pathology and
biochemical phenotype in b-hydroxyisobutyryl-CoA
hydrolase (HIBCH) deficiency, a disorder of the fifth step
of valine oxidation with a Leigh-like phenotype and defi-
ciency of multiple mitochondrial enzymes.4,5 Very
recently, ECHS1 mutations were reported in two siblings
with Leigh disease and remarkable clinical and biochemical
similarities to HIBCH deficiency.6 Both presented soon
after birth with generalized hypotonia, poor feeding,
respiratory insufficiency, and developmental delay. They
suffered a severe clinical course and died at the age of 4
and 8 months.
Here, we report 10 unrelated individuals, identified by
exome sequencing, who carry compound heterozygous or
homozygous ECHS1 mutations and present with a combi-
nation of (Leigh-like) mitochondrial encephalopathy,
deafness, epilepsy, optic nerve atrophy, and cardiomyopa-
thy. This work confirms ECHS1 mutations as a cause of
mitochondrial disease, and defines the broad phenotypic
spectrum of this new disorder which ranges from fatal
neonatal courses to survival into adulthood.
Patients and Methods
Written informed consent was obtained from all patients
investigated or their guardians and the ethics committee
Figure 1. Short-chain enoyl-CoA hydratase (ECHS1) functions. Proposed functions of ECHS1 in the mitochondrial amino acid and fatty acid
metabolism with illustration of the level of HIBCH (3-hydroxyisobutyryl-CoA hydrolase) deficiency.
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of the Technische Universit€at M€unchen approved the
study. The patients tested positive for ECHS1 mutations
are part of a large cohort of cases with suspected mito-
chondrial disorders. DNA samples have been collected
for genetic analyses in three different centers including
Bern (Switzerland, 47 cases including family F2), Saitam-
a (Japan, 180 cases including families F1 and F6), and
Munich (Germany, 435 cases including families F3-5
and 7-10; Fig. 2). Clinical and biochemical findings of
ECHS1 mutation-positive patients are summarized in
Table 1 and representative abnormal magnetic resonance
imaging (MRI) findings are shown in Figure 3. In addi-
tion, we report on four older siblings who have died
undiagnosed with a clinical picture similar to the mito-
chondrial encephalocardiomyopathy described in their
younger siblings with a confirmed diagnosis of ECHS1
deficiency.
Regarding terminology, we avoided the term “Leigh syn-
drome” or “Leigh-like syndrome” for the whole group of
our patients with ECHS1 deficiency, because these are ill-
defined entities and many of our patients did not fulfill the
criteria suggested by Rahman et al.7 In those individual
cases that fulfilled the definition by Rahman, we preferred
to use the more neutral term “Leigh-like syndrome” or
“Leigh-like pattern in MRI”.
Case reports
Patient #346 (F1, II:2, c.[176A>G];[476A>G], p.[Asn59-
Ser];[Gln159Arg]), a girl, was born after a normal preg-
nancy at 39 weeks of gestation with normal birth
measurements (weight 2935 g, length 50.5 cm) as the sec-
ond child of unrelated Japanese and American parents.
Soon after birth, she was admitted to a neonatal medical
center for severe respiratory and cardiac failure with
hypertrophic cardiomyopathy (HCM) and suspected deaf-
ness. There was profound lactic acidosis in blood (21–
43 mmol/L, lower limit of normal 1.8 mmol/L), but met-
abolic profiling (amino acid analysis, urine organic acid
analysis, acylcarnitine analysis) was unremarkable. Brain
MRI at day 8 showed low intensity in cerebral white mat-
ter, and moderate brain atrophy at day 58. She died at
the age of 4 months and autopsy was performed. Respira-
tory chain analysis showed mild deficiency of complex I
in liver, but normal activities in muscle and heart. Her
older sister died due to respiratory failure and severe lac-
tic acidosis on her first day of life.
Patient #42031 (F2, II:1, c.[197T>C];[449A>G],
p.[Ile66Thr];[Asp150Gly]), a boy, is the first child of
healthy nonconsanguineous Swiss parents. After a nor-
mal pregnancy, he was born at 42 weeks of gestation
with normal birth measurements. Postnatally, he devel-
oped lactic acidosis and neonatal seizures. Analysis of
fibroblasts showed reduced pyruvate oxidation compati-
ble with a complex I or pyruvate dehydrogenase defect,
whereas enzymatic activities of the respiratory chain in
muscle and fibroblasts were normal. These findings led
to a therapeutic trial with ketogenic diet. The diet was
stopped after a few months as no clinical response was
observed. At 5 months of age, he had severely delayed
motor development, hardly any head control, severe
truncal hypotonia and intermittent episodes of opisthot-
onus. There was no reaction to visual or auditory stim-
uli. Despite gastric tube feeding, the child was severely
underweight (2.8 SD), of short stature (3.4 SD), and
microcephalic (4.9 SD).
Laboratory investigation revealed persistently elevated
lactate (2.4–6.0 mmol/L), mildly elevated CK and repeat-
edly normal acylcarnitines. Repeated electroencephalo-
grams did not show epileptic discharges. Brain MRI at
age 17 days showed normal myelinisation but symmetri-
cal punctiform hyperintensities in the centrum semiovale.
MR spectroscopy of basal ganglia showed elevated lactate.
Ophthalmological examination suggested bilateral optic
atrophy, and acoustic evoked potentials confirmed severe
sensorineural deafness. At the age of 11 months, the child
was found dead in his bed. Autopsy revealed morphologi-
cal and histological findings of subacute necrotizing
encephalopathy (Fig. 3E) and massive left ventricular
hypertrophy.
Patient #68552 (F3, II:6, c.[476A>G];[476A>G],
p.[Gln159Arg];[Gln159Arg]), a girl, is the sixth child of
first cousins of Pakistani origin. Shortly after birth, the
infant was found hypotonic with poor feeding and with
high lactate (5.1 mmol/L). She was extremely irritable
and had episodes of stiffness but electroencephalography
(EEG) was normal. Even so, the baby was started on an-
tiepileptic drug therapy as well as on baclofen. She was
fed continuously by nasogastric tube. She showed no
developmental progress nor developed any meaningful
interaction with her environment and her irritability
worsened episodically. Palliative care was instituted and
she died aged 2 years and 4 months.
Brain MRI showed symmetrical white matter changes
with a periventricular focus and extension into the subcor-
tical areas of the frontal and parietal lobes. The thalami as
well as the caudate and lentiform nuclei appeared normal.
MR spectroscopy of basal ganglia showed no obvious
lactate peak. Neonatal adrenoleukodystrophy, biotinidase
deficiency, Krabbe disease, GM1 gangliosidosis and meta-
chromatic leukodystrophy were excluded biochemically.
There were no significant abnormalities of acylcarnitines,
organic acids, glycosaminoglycans, oligosaccharides or
amino acids (except a raised alanine in keeping with lactic
acidosis). Invasive investigations such as muscle biopsy
were refused.
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Figure 2. Pedigrees of investigated families and short-chain enoyl-CoA hydratase (ECHS1) structure and conservation of identified mutations. (A)
Pedigrees of 10 families with mutations in ECHS1. Mutation status of affected (closed symbols) and unaffected (open symbols) family members.
(B) Gene structure of ECHS1 with known protein domains of the gene product and localization and conservation of amino acid residues affected
by mutations. Intronic regions are not drawn to scale.
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Molecular genetic screening demonstrated a maternally
transmitted m.1555A>G MTRNR1 mtDNA mutation that
is characteristically associated with aminoglycoside-
induced hearing loss. This was not felt to be responsible
for the patient’s condition.
Three older siblings of this patient had congenital lactic
acidosis and died between the ages of 1 and 2 years. The
first two affected children were identical twin girls and
the third affected child was a boy. The history is identical
in all three children. They were all born at term via nor-
mal vaginal delivery. There was no history of birth
asphyxia and they were apparently well soon after birth.
They fed well initially but became symptomatic aged
between 1 and 2 days with generalized tonic-clonic sei-
zures. Subsequently, they had poor feeding and severe
developmental delay. The seizures were recurrent but well
controlled with anticonvulsants. They were tube-fed from
the first few days of life as they were unable to suck and
swallow effectively. They had severe developmental delay
from the outset and showed little evidence of develop-
ment during infancy. They always had a poor head con-
trol, poor eye contact, and a poor smile. They were never
able to reach out and their hearing was possibly impaired.
There was no history of dystonia and they were said to be
very hypertonic. There were no breathing problems
reported. They apparently had no renal tubular acidosis
but they required some treatment with bicarbonate for
metabolic acidosis (lactate levels of ~5.0 mmol/L). There
was no history of cardiac or liver involvement. The twin
girls died aged 2 years and the boy died aged 1 year. In
the twin girls, a diagnosis of complex I deficiency was
established on muscle biopsy respiratory chain enzyme
analysis. Testing of ECHS1 performed on newborn
screening bloodspots of the twin older siblings (F3, II:1
and II:2) confirmed that they were also homozygous for
the c.476A>G, p.Gln159Arg variant. The children were
treated with sodium bicarbonate, anticonvulsants, and a
mitochondrial vitamin cocktail as well as nasogastric tube
feeding. The family has two other healthy girls, now
teenagers.
Patient #68761 (F4, II:1, c.[161G>A(;)817A>G]
p.[Arg54His(;)Lys273Glu]), a boy, is the first child to
healthy unrelated parents from The Netherlands. After a
normal pregnancy, he was born at gestational age
39 + 1 weeks by Cesarean section on maternal indication
with a birth weight of 3990 g. Apgar scores were 8 after
1 min and 9 after 5 min. Mild generalized muscular
hypotonia was observed upon birth which was accompa-
nied by feeding problems until the age of 5 months.
Thereafter, his clinical condition declined and he devel-
oped severe encephalopathy with hardly any spontaneous
movements of the head and trunk, swallowing problems,
and episodes of inconsolable crying. He depended onTa
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tube feeding and suffered from epilepsy with hypsarrhyth-
mia and multifocal epileptic activity in the EEG at the
age of 1 and 3 years.
On physical examination, he was unable to make con-
tact or follow objects, showed virtually no spontaneous
movements, but only dystonic movements of arms and
legs. Over the course of the disease axial hypotonia and
hypertonia of the limbs persisted, dystonic movements
diminished, and he did not make any developmental
progress. Laboratory tests showed chronic iron deficiency
leading to anemia. Physical examination at the age of
6 years showed microcephaly, scoliosis, and muscular
hypotonia. The child died at the age of 7.5 years due to
respiratory insufficiency in the course of a pulmonary
infection.
Brain MRI at the age of 1 year showed atrophy of cau-
date nuclei, corpus callosum, mesencephalon, and pons.
These changes were progressive at age 4 years showing
extensive white and gray matter brain atrophy, mainly in
frontal and temporal lobes bilaterally with subsequent
widening of the subarachnoid space and of ventricular
system. Brain MR spectroscopy showed an overall
decrease in NAA being most pronounced in the basal
ganglia but no elevation of lactate.
Cardiac ultrasound at the ages of 1 and 4 years showed
no structural or functional abnormalities. Biochemical
analysis of a skeletal muscle specimen showed normal
citrate synthase (CS)-adjusted activities of respiratory chain
complexes I–V but a decreased overall ATP production.
Pathogenic mutations of the mitochondrial DNA were
excluded by Sanger sequencing of DNA from muscle.
Patient #73663 (F5, II:3, c.[673T>C];[673T>C],
p.[Cys225Arg];[Cys225Arg]), a girl, was born at term as
the third child of consanguineous parents after normal
pregnancy and spontaneous vaginal delivery. On day 5,
she was admitted to hospital due to rapid loss of body
weight (24% below birth weight) and severe metabolic
acidosis (pH 6.86). Lactate, alanine, and ketone bodies
were also strongly increased leading to the suspicion of
an inherited disorder of mitochondrial energy metabo-
lism. Following this neonatal decompensation she showed
a severe global development delay, severe generalized
spastic tetraparesis, myoclonic epilepsy, and HCM. At age
16 months, she had a cardiac arrest following a diagnostic
muscle and skin biopsy. She survived after 45 min of car-
diopulmonary resuscitation but several complications
followed this event (ARDS, sepsis, aspiration pneumonia,
acute renal failure, and acute hepatic failure). At age
2.3 years she does not show active movement of arms
and legs and is not able to sit, stand or walk. She neither
speaks nor fixes or follows persons and objects. She reacts
to voices and noise.
Cranial MRI performed at age 13 months showed
delayed myelination, a thin corpus callosum, and T2 sig-
nal abnormalities in the periventricular white matter.
Lesions in putamen and globus pallidus were also found.
MR spectroscopy of gray and white matter was normal.
Metabolic work-up revealed elevated serum lactate (up to
8.5 mmol/L), moderately elevated plasma alanine (up to
630 lmol/L), slightly elevated ethylmalonic acid in urine
(60 mmol/mol creatinine), and intermittently low plasma
ketone bodies in preprandial state. Hyperuricemia was
found. Acylcarnitine profiling was normal. Radiometric
and single enzyme analysis of OXPHOS in frozen muscle
tissue did not confirm the suspected diagnosis of a mito-
chondrial disorder.
A brother of this girl has died at age 4 months during
an acute decompensation similar to that described above.
He also had severe developmental delay, elevated lactate
and metabolic acidosis. Similar to his younger sister, liver,
A C D EB
Figure 3. Spectrum of brain MRI and autopsy changes in ECHS1 patients. (A) MRI (T2) at age 8 days in individual F1, II:2 showing widespread
diffuse white matter changes and brain atrophy. (B) MRI (T2) at age 8 months in individual F6, II:1 (#376) showing brain atrophy and bilateral
symmetric signal hyperintensity in caput nucleus caudatus and putamen. (C) MRI (FLAIR) at age 2.2 years in individual F9, II:2 (#57277) showing
increased signal in putamen, globus pallidus and caput nucleus caudatus. (D) MRI (FLAIR) at age 15 years in individual F10, II:1 (#52236) showing
bilateral symmetric signal hyperintensity in caput nucleus caudatus and putamen. (E) Autopsy at age 11 months in individual F2, II:1 (#42031)
showing necrotizing encephalopathy of the caudate and lenticular nuclei. MRI, magnetic resonance imaging; ECHS1, short-chain enoyl-CoA
hydratase.
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skin, and muscle biopsy did not confirm a respiratory
chain defect in this child.
Patient #376 (F6, II:1, c.[98T>C];[176A>G], p.[Phe33-
Ser];[Asn59Ser]), a girl, was born after an uneventful
pregnancy at 39 weeks of gestation with normal birth
measurements (weight 3124 g, length 51 cm) as the first
child of unrelated Japanese parents. At the age of 2 days,
she had epileptic seizures and was treated with phenobar-
bitone. In her first months, developmental delay and
muscular hypotonia were noted. At the age of 8 months,
she developed respiratory failure and unconsciousness,
and was admitted to hospital. Transient lactic acidosis in
blood (8.0 mmol/L, lower limit of normal 1.8 mmol/L)
was found. Metabolic profiling (amino acid analysis, urine
organic acid analysis, and acylcarnitine analysis) was
unremarkable. Brain CT and MRI at 8 months showed
symmetrical, bilateral signal abnormalities in basal gan-
glia, and she was diagnosed with Leigh-like syndrome. At
the age of 1 year, she developed deafness, and at the age
of 3 years dilated cardiomyopathy. Muscle biopsy showed
mild deficiency of complex IV.
Patient #76656 (F7, II:2, c.[268G>A];[583G>A],
p.[Gly90Arg];[Gly195Ser]), a girl, is the child of healthy
unrelated German parents. After a normal pregnancy, she
was born at term with normal birth measurements. The early
motor development was normal, and she started walking at
the age of 14 months. The girl was referred at age 2 years
because of stiffness of gait and a tendency to fall. At admis-
sion, she showed muscular hypotonia, coordination prob-
lems, choreoathetotic movements, delayed speech
development, and sensorineural deafness, which had been
treated with hearing aids. Blood chemistry was normal
including lactate, amino acids and organic acids.
Brain MRI at age 2 years showed no cerebral, cerebel-
lar, or callosal atrophy but mild bilateral signal hyperin-
tensities of putamen, globus pallidus, nucleus caudatus,
and periventricular white matter. MR spectroscopy of
basal ganglia showed mild elevation of lactate.
A muscle biopsy showed only unspecific morphologic
findings, and biochemical analysis of respiratory chain
activities was unremarkable.
Patient #MRB166 (F8, II:1, c.[161G>A];[394G>A],
p.[Arg54His];[Ala132Thr]), a girl, is the first child of
healthy unrelated German parents. Pregnancy was compli-
cated by oligohydramnion and a diagnosis of gastroschi-
sis. She was born by Cesarean section at 34 weeks of
gestation with normal birth measurements (weight 1490 g
[3rd percentile], length 41 cm [25th percentile], and head
circumference 31 cm [25th percentile]). Surgical correc-
tion of gastroschisis was performed. The girl needed
phototherapy for icterus neonatorum, tube feeding, and
assisted ventilation. Deafness was diagnosed with 2 years
of age and treated by cochlear implants. One seizure was
observed at the age of 7 years. She showed truncal hypo-
tonia, gait ataxia, and severe developmental delay (crawl-
ing at 1.5 years, sitting at 3 years, assisted walking at
5 years of age and no speech at 8 years). She has an oval
face, a broad nasal tip, a large mouth, a high arched pal-
ate, and a receding chin. MLPA PWS/AS, UBE3A, and
MECP2 mutation analysis and microarray gave normal
results.
Patient #57277 (F9, II:2, c.[161G>A];[431dup],
p.[Arg54His];[Leu145Alafs*6]), a girl, is the second child
of healthy nonconsanguineous parents from Germany.
She was born after a normal pregnancy at 41 weeks of
gestation with normal body measurements. Early motor
development was delayed, and she never acquired the
ability to sit or walk independently. Acquisition of lan-
guage was impeded by sensorineural deafness for which
she was fitted with hearing aids. At 18 months parents
noted a pendular nystagmus with a rotatoric component
as well as loss of central vision due to optic atrophy.
Residual vision at 10 years was 0.3. From 2 years of age
her motor abilities deteriorated during episodes of febrile
illness and lactic acidemia when she developed a move-
ment disorder that undulated between dystonia (opisthot-
onus) and chorea. Treatment with Levodopa/Carbidopa
worsened her symptoms. She is presently 16 years old.
Her body length is at and her weight 1 kg below the third
percentile. Due to dysphagia and her inability to chew she
has to be fed minced food. Massive caries and enamel
defects from trismus required general dental repair and
reconstruction under anesthesia. She visits a secondary
school for disabled children, and communicates through
a voice computer by saying “yes” or “no” or by making
hand gestures.
Cranial MRI at the age of 1.5 years showed Leigh-like
lesions with increased T2-signal intensity in the putamen
and globus pallidus which became more prominent until
age 2.2 years (Fig. 3C). Proton spectroscopy in the basal
ganglia showed an increased lactate peak. Laboratory
examinations revealed mildly increased urine excretion of
lactate and lactic acidemia (2.5–4.0 mmol/L). The amino
acid profile was normal in cerebrospinal fluid (CSF) and
plasma. CPK was normal and muscle biopsy at 2 years of
age only showed unspecific myopathic changes. Biochemi-
cal investigation revealed normal activities for the OX-
PHOS complexes, CS, PDHc as well as in vitro pyruvate
oxidation.
Patient #52236 (F10, II:1, c.[229G>C];[476A>G],
p.[Glu77Gln];[Gln159Arg]), a girl, is the first child of
healthy unrelated German parents. After a normal preg-
nancy, she was born at 42 weeks of gestation with normal
birth measurements (weight 3120 g, length 51 cm).
Motor development was considered normal during the
first months of life, and she started walking at the age of
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11 months. From this age, however, short episodes of fist
clenching, teeth gnashing, horizontal nystagmus and unre-
sponsiveness were noted. Although repeated EEG did not
show epileptic discharges, treatment with phenytoin was
started and maintained until age 5 years when the attacks
disappeared. From age 17 months, progressive gait abnor-
malities were observed. These were episodic in the begin-
ning, but evolved into a paraspastic gait in early
childhood, and the girl became wheelchair-dependent at
age 9.5 years. From age 2 years, visual problems became
evident, and examination showed bilateral optic atrophy.
Visual acuity at age 13 years was 1/50 for both eyes. From
age 7 years, progressive sensorineural deafness was found,
and the patient was supplied with hearing aids at age
9.5 years. At the same age, mild mental retardation and
dysarthria were noted. The patient completed a secondary
school for blind children, and has been working in a
workplace for disabled persons from age 18 years.
Examination at age 31 years showed short stature
(155 cm) and low body weight (40 kg). Visual acuity was
off-chart, the patient could only notice hand movements,
and there was a pendular nystagmus of the blind. Com-
munication was impeded by severe dysarthria. She had
generalized dystonia and a spastic tetraparesis, leading to
an inability to walk independently. Sensation was entirely
normal.
Electromyography (EMG), neurography and repeated
EEG were normal. Laboratory examinations showed
mildly elevated lactate (2.5 mmol/L, normal <1.8 mmol/
L) in CSF and inconsistently in serum (2.0–2.8 mmol/L,
normal <2.2 mmol/L). A muscle biopsy at age 9 years
showed some type II fiber atrophy due to immobilization
and a faint accumulation of lipid droplets in single fibers.
There were no ragged red fibers (RRF) and no cyto-
chrome c oxidase (COX) deficiency, and biochemical
analysis of respiratory chain activities showed normal
results. Brain MRI at age 15 years showed exclusively
Leigh-like signal hyperintensities in the caput nuclei caud-
ati and putamen bilaterally (Fig. 3D). MR spectroscopy of
the left putamen showed no elevation of lactate.
Genetic analysis
We used a dual approach of exome sequencing and panel
sequencing to analyze a cohort of patients with suspected
mitochondrial disorders. Seven index patients (#52236,
#57277, #68552, #68761, #73663, #76656, and #MRB166)
were investigated by exome sequencing in Germany as
described previously.8,9 In brief, we used a SureSelect
Human All Exon 50 Mb Kit (Agilent) for enrichment and
a HiSeq2500 (Illumina) for sequencing. Reads were
aligned to the human reference assembly (hg19) with
BWA (version 0.5.8 Open source software, Wellcome
Trust Sanger Institute). More than 90% of the exome was
covered at least 209 allowing for high-confidence variant
calls. Single-nucleotide variants (SNVs) and small inser-
tions and deletions were detected with SAMtools (version
0.1.7 Open source software, Wellcome Trust Sanger Insti-
tute). Variant prioritization was performed based on
the autosomal-recessive patterns of inheritance and the
notion that the clinical mitochondrial phenotype of the
patients is very rare. We therefore excluded variants with
a frequency higher than 0.1% in 3850 control exomes and
public databases and focused on genes encoding mito-
chondrial proteins10 carrying two potentially pathogenic
DNA variants. In two other patients (#346 and #376) we
used a TruSeq Exome kit from Illumina. A detailed
description of the bioinformatic pipeline and variant fil-
tering used for these two cases has been published
recently.11
In patient #42031 we applied targeted enrichment of
1476 nuclear genes (including 1013 genes coding for
mitochondrial proteins according to the MitoCarta) using
an in-solution hybridization capture method (NimbleGen
Madison, WI, USA). Paired-end sequencing was per-
formed on a HiSeq2500 (Illumina) to an average 1789
coverage. Sequence alignment and variant calling was
done with CLC Workbench v.7.0.4. CLC bio, Aarhus,
Denmark
We used Sanger sequencing to confirm all identified
ECHS1 mutations and to test the carrier status of avail-
able family members. Primer sequences and PCR condi-
tions are available upon request.
Western blotting
Immunoblotting was performed using two different pro-
tocols. For the analysis of F2;II:1 (#42031), F10, II:2
(#52236), F9,II:2 (#57277), F5, II:3 (#73663) 45 lg of
protein of patients’ fibroblast cell homogenates were sepa-
rated on 13% sodiumdodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) along with a protein stan-
dard (Precision Plus Protein Kaleidoscope, Biorad Her-
cules, CA, USA) and blotted onto polyvinylidine fluoride
membranes (Immobilon, Merck Millipore Darmstadt,
Germany). Primary antibodies were as follows: ECHS1
(66117, Proteintech Chicago, IL, USA), b-actin (ab13822,
Abcam Cambridge, UK). Chemiluminescence detection
was performed on an Odyssey Biomedical: Phoenix, AZ,
USA infrared imaging system according to the manufac-
turer’s instructions. For the analysis of F1, II:2 (#346),
and F6, II:1 (#376) mitochondria were isolated by
homogenization of cells in mitochondrial isolation buffer
(20 mmol/L HEPES, 4-(2-hydroxyethyl)-1-piperazineetha-
nesulfonic acid pH 7.4, 220 mmol/L mannitol, 70 mmol/L
sucrose, 1 mmol/L Ethylenediaminetetraacetic acid) with
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2 mg/mL Bovine serum albumin. Cell homogenates were
centrifuged at 700g at 4°C for 5 min and postnuclear
supernatant was collected. Mitochondria were pelleted by
centrifugation at 10,000g at 4°C for 5 min and
mitochondrial pellet was resuspended in mitochondrial
isolation buffer for subsequent size-separation on 10%
gels by SDS-PAGE, and transfer to a methanol-activated
PVDF membrane. Immunoblotting was performed with
primary antibodies from GeneTex (ECHS1) and Abcam
(HSP60). Chemiluminescence detection was achieved with
ECL Select (GE Healthcare, Little Chalfont, UK) and the
membrane was viewed with the LAS4000 (GE Healthcare,
Little Chalfont, UK), according to the manufacturer’s
instructions.
Analysis of 2-enoyl-CoA hydratase activity
2-enoyl-CoA hydratase (ECHS1) activity was measured
spectrophotometrically in fibroblast cell lysates following
the absorbance of the unsaturated substrate crotonyl-CoA
over time (15 min) as described.12,13 Briefly, trypsinized
fibroblasts were resuspended in reduced Triton-X-100
(0.2%) and lysed by sonification. Lysates were centrifuged
at 700g for 5 min to remove cellular debris and protein
concentrations were determined in supernatants by the
BCA method. The reaction mixture consisted of:
100 mmol/L potassium phosphate buffer (pH 8) for a
final concentration of, 0.1 mg/mL BSA and 50 lL of cell
homogenate for a total of 15 lg of protein. The reaction
was started with 50 lL of 250 lmol/L crotonyl-CoA for a
final concentration of 25 lmol/L. Samples were measured
at 37°C in UV cuvettes at 263 nm in a Shimadzu spectro-
photometer. Enzymatic activity was calculated using a
molar extinction coefficient of 6700. Enzymatic activity
was normalized to the mitochondrial marker enzyme CS
as previously described.14 All reactions were performed in
at least three independent experiments in triplicates with
similar findings.
Palmitate loading assay
Palmitate loading in human skin fibroblasts of ECHS1
patients, healthy volunteers as negative controls and fibro-
blasts of patients with short- and medium-chain acyl-CoA
dehydrogenase (MCAD) deficiency as disease controls
were performed as previously described.15 In brief, cell
cultures were maintained in Dulbecco’s modified Eagle
medium (Invitrogen, Darmstadt, Germany) supplemented
with 2 mmol/L glutamine, 10% fetal calf serum, 1% peni-
cillin/streptomycin, and FungizoneTM (all from Invitrogen)
at 37°C and 5% CO2 in a humidified atmosphere until
confluency. Palmitate loading was performed in serum-
and glutamine-free minimal essential medium (Invitro-
gen) containing palmitic acid (200 lmol/L; Sigma-Aldrich
Taufkirchen, Germany), L-carnitine (400 lmol/L; Sigma),
and bovine serum albumin (0.4%; fatty acid-free; Sigma).
After the end of the 96 h-incubation period, 10 lL aliqu-
ots of the cell culture media were collected and mixed
with isotope-labeled internal standard (Cambridge Isotope
Laboratories, Tewksbury, MA 01876) in methanol.
Twenty-five microliters of the butylated sample were used
to analyze the acylcarnitine profile by tandem mass spec-
trometry. For each sample at least two independent mea-
surements were performed. The acylcarnitine
concentration was normalized to the protein content of
the fibroblast sample and expressed as nmol/mg protein.
For the analysis of palmitate-dependent mitochondrial
respiration, control and patient fibroblasts were seeded at
a density of 20,000 cells/well in 80 lL of high glucose Dul-
becco’s modified media (Gibco:Life Technologies, Darm-
stadt, Germany) supplemented with 10% fetal bovine
serum (Invitrogen), 1% penicillin-streptomycin (Invitro-
gen) and 200 lmol/L uridine (Sigma) in a XF 96-well cell
culture microplate (Seahorse Bioscience, North Billerica,
MA, USA) and incubated overnight at 37°C in 5% CO2.
Culture medium was replaced with 160 lL of serum- and
glutamine-free minimal essential medium (Invitrogen)
supplemented with L-carnitine (400 lmol/L; Sigma), and
bovine serum albumin (0.4%; fatty acid-free; Sigma) and
cells were incubated for 24 h at 37°C in 5% CO2. Palmi-
tate-BSA complex was prepared according to the manufac-
turer’s protocol (Seahorse Bioscience). Oxygen
consumption rate (OCR) was measured using a XF16
Extracellular Flux Analyzer 2 (Seahorse Biosciences). OCR
was determined with no additions; after addition of BSA
(30 lmol/L) or palmitate-BSA conjugate (180/30 lmol/L).
Results
Exome sequencing identifies ECHS1
mutations
We applied whole exome sequencing in a cohort of 435
individuals with a suspected disorder of mitochondrial
energy metabolism and identified six unrelated affected
individuals carrying two heterozygous or homozygous rare
variants (minor allele frequency [MAF] <0.1%) in ECHS1
(Fig. 2). Applying the same variant selection criteria to
our in-house exome datasets from 3850 patients referred
with presumed nonmitochondrial phenotypes revealed
rare recessive-type ECHS1 variants in one additional index
case, F8, II.1 (#MRB166, Fig. 2). This patient was investi-
gated in the context of an intellectual disability study but
the relevance of the ECHS1 variants was hitherto unclear.
Clinical follow-up and review of medical reports revealed,
however, that the neurologic features of this patient
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(deafness, seizures, hypotonia, ataxia, and developmental
delay) are very well compatible with a mitochondrial dis-
order. In contrast, it remains unclear whether the dysmor-
phic signs in this patient are related to the ECHS1
deficiency as dysmorphism is rather uncommon in mito-
chondrial diseases and was not found in any of the other
ECHS1-deficient patients. The enrichment of rare biallelic
ECHS1 variants in genomes of individuals with a sus-
pected mitochondrial disorder (n = 7) compared to 3850
control genomes was genome-wide significant
(P < 1.1 9 107, Fisher exact test). In addition, in several
individuals, ECHS1 was the only gene coding for proteins
with a predicted or confirmed mitochondrial localization
harboring two rare DNA variants. We gained further evi-
dence for a disease association of ECHS1 by exome
sequencing of 180 Japanese individuals with suspected
mitochondrial disorders which identified two additional
ECHS1-mutant individuals, F1, II.2 (#346) and F6, II.1
(#376, Fig. 2). By panel sequencing in a further patient
with a similar clinical presentation we identified two het-
erozygous ECHS1 mutations in F2, II:1 (#42031, Fig. 2).
The combined approaches of exome and candidate gene
sequencing identified a total of 13 different disease alleles
in ten index patients. Pedigrees of investigated families
and localization of identified ECHS1 mutations as well as
the evolutionary conservation of affected amino acid resi-
dues are shown in Figure 2B. All ECHS1 mutations were
confirmed by Sanger sequencing in the index patients.
Carrier testing of available parental samples confirmed a
biallelic localization of the mutations. DNA from the par-
ents was not available in families F4 and F6, however, in
the latter a compound heterozygous state of the mutations
was confirmed by haplotype phasing. The healthy siblings
of families F10, F9, F3, and F7 were either wild-types or
heterozygous carriers. For families F3, F5, and F1, family
history was positive for the occurrence of similar clinical
conditions but no DNA samples were available for molec-
ular tests from individuals F1, II:1 and F3, II:3.
Of the 13 different ECHS1 mutations identified in our
cohort, only one, c.431dup, p.Leu145Alafs*6, predicts a
premature truncation and loss of function of the protein
(Table S1). All other detected mutations are missense
variants, indicating that a complete loss of ECHS1 func-
tion may be embryonic lethal. With the exception of the
c.268G>A, p.Gly90Arg variant, all are predicted to be dis-
ease-causing (MutationTaster2).16 Although all variants
are rare (MAF < 0.05%), three mutations were identified
in more than one family (c.161G>A, p.Arg54His, n = 3;
c.176A>G, p.Asn59Ser, n = 2; and c.476A>G,
p.Gln159Arg, n = 2), in each case with different muta-
tions on the other allele. In addition, the c.476A>G,
p.Gln159Arg mutation was found in the homozygous
state in a third, consanguineous family. However, there is
no mutational hotspot and the identified mutations are
distributed across all eight coding exons of ECHS1 except
for exons 1 and 7 (Fig. 2B).
Functional consequences of ECHS1
mutations
Next, we analyzed the consequences of ECHS1 mutations
in fibroblast cell lines. In six cell lines, we investigated
ECHS1 protein levels and in four of them we measured
2-enoyl-CoA hydratase activity. SDS-PAGE separation of
mitochondrial fractions and total cell lysates followed by
immunodetection with an antibody against ECHS1
revealed a severe decrease in ECHS1 steady-state levels in
all patient-derived fibroblast cell lines. To test the func-
tional impact of ECHS1 mutations, we determined
2-enoyl-CoA hydratase activity in the fibroblasts cell ly-
sates from individuals F2, II.1 (#42031), F10, II:2
(#52236), F9, II:2 (#57277), and F5, II:3 (#73663). The 2-
enoyl-CoA hydratase activity was markedly reduced in
patients’ cell lines with residual activities varying between
14% and 50% of controls (Fig. 3B).
Palmitate loading in fibroblasts of three ECHS1
patients induced an acylcarnitine profile very similar to
that of short-chain acyl-CoA dehydrogenase (SCAD) defi-
ciency. The characteristic metabolite, butyrylcarnitine,
increased to 170%, 199%, or 273% of the upper normal
range of the controls. In another ECHS1-deficient patient,
however, butyrylcarnitine was within the range of controls
(48% of the upper normal range). In comparison, buty-
rylcarnitine increased to 388% of controls in patient fi-
broblasts with SCAD deficiency and 44% in MCAD
deficiency. These results indicate that ECHS1 deficiency
results in a mild functional disorder of short-chain fatty
acid oxidation.
This notion is further supported by the observation of
reduced palmitate-dependent respiration in patient-
derived fibroblasts compared to controls (Fig. 4C). Note-
worthy, in the three cell lines tested for both 2-enoyl-CoA
hydratase activity and palmitate-dependent respiration,
the severity of defects correlated. Together, these data
provide evidence for the pathogenicity of eleven ECHS1
alleles.
Organic acids in urine
In analogy, organic acid analysis by gas chromatography/
mass spectrometry in urine of patient #73663 revealed
slightly elevated concentrations of ethylmalonate, a key
metabolite of SCAD deficiency. Functional deficiency of
short-chain fatty acid oxidation was also shown by inter-
mittently elevated plasma fatty acids (250–780 lmol/L;
normal <300 lmol/L) with concomitantly low normal
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plasma ketone bodies (65–90 lmol/L; normal <200 lmol/
L) in postprandial state of some patients. However, keto-
genesis was only mildly impaired which was shown by a
mild increase in ketone bodies during catabolism (570–
630 lmol/L, normal <3000 lmol/L). In addition, we
identified 2-methyl-2,3-dihydroxybutyrate which likely
derives from acryloyl-CoA or, alternatively, methacrylyl-
CoA, both metabolites of valine oxidation, in urines of
four ECHS1 patients. This metabolite correlated with
disease severity as its concentration was 229-fold higher
than the median value in 35 controls in the severely
affected patient #42031 (onset at birth, died at
11 months), 39-fold higher in patient #73663 (onset on
day 5, alive at 2 years), sixfold higher in patient #76656
(onset at 2 years, alive at 5 years), and even in the
normal range in the mildest affected case #52236 (onset
at 11 months, alive at 31 years), the only patient who
survived into adulthood.
Phenotypic features of ECHS1 deficiency
In contrast to gene identification strategies in which an a
priori phenotypic stratification of the investigated cohort
was the main key to success,17 this group of ECHS1-
mutant individuals was identified by exome sequencing of
a large cohort of individuals with suspected mitochon-
drial disorders. This approach allows for a rather unbi-
ased assessment of the phenotypic spectrum associated
with ECHS1 deficiency.
Disease severity ranged from presentations with neona-
tal onset and death in early infancy to survival into adult-
hood. In nine of 10 affected individuals, pregnancy was
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Figure 4. Analysis of ECHS1 levels and enzymatic activity. (A) Analysis of ECHS1 steady state levels by immunoblotting show a decrease in the
amount of ECHS1 in patient-derived cell lines compared to controls. (B) Analysis of residual ECHS1 enzymatic activity indicates reduced 2-enoyl-
CoA hydratase activity in cell lysates from patients’ fibroblasts compared to controls. Results shown are from at least three experiments
performed in triplicates and controls (n = 4). Boxplot whiskers indicate range from 5th to 95th percentile. *P < 0.001; two-tailed unpaired t-test.
(C) Analysis of palmitate-dependent OCR in fibroblast cell lines revealed impaired respiration in patients’ cells in comparison to controls. The
experiment was performed several times with very similar results. The data are shown from one experiment performed with more than 10
replicates for each cell line grown and treated in parallel. Error bars indicate 1 SD. *P < 0.001; two-tailed unpaired t-test. ECHS1, short-chain
enoyl-CoA hydratase; OCR, oxygen consumption rate.
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normal and the children were born at term with normal
body measurements. First clinical signs appeared in the
prenatal period in one individual (oligohydramnios) and
in the neonatal period (first month) in seven. Presenting
signs included epileptic seizures, muscular hypotonia,
respiratory and cardiac failure, failure to thrive, elevated
lactate, and metabolic acidosis. In the two mildest affected
individuals, developmental delay (F9, II:2, #57277) or epi-
sodic neurological symptoms (F10, II:1, #52236) were
noted in the first year of life and lactate elevations were
only intermittent and mild. While six of 10 affected indi-
viduals are still alive at the age of 2, 3, 5, 8, 16, and
31 years, four died at the age of 4, 11, 28, and 90 months,
respectively. Interestingly, cardiomyopathy was only found
in the individuals with a severe course and early death
and none of the patients over 3 years of age.
In the course of the disease, neurological signs are most
prominent including sensorineural deafness (9/9), devel-
opmental delay (8/10), epileptic seizures (6/9), dystonia
(5/9), optic atrophy (6/10), muscular hypotonia (6/10),
and spastic paresis (2/10). Other clinical features include
cardiomyopathy (4/10) and respiratory failure (3/10).
Increased blood, urine, and CSF lactate levels were found
in seven of 10 individuals. Brain MRI was performed in
nine of 10 individuals and showed white matter changes
and brain atrophy in the very severe, early onset cases
(n = 5) and Leigh-like bilateral T2 hyperintensities in the
basal ganglia (nucleus caudatus, putamen, and globus pal-
lidus) in the less severely affected individuals (n = 4;
Fig. 3). MR spectroscopy of basal ganglia showed elevated
lactate concentrations in three of seven individuals.
Taken together, our findings identified ECHS1 muta-
tions as a cause of a new clinical entity characterized by
an early onset, very severe (Leigh-like) mitochondrial
encephalopathy with deafness, epilepsy, optic atrophy,
and cardiomyopathy. Consistently elevated plasma con-
centrations of lactate indicate a dysfunction of the mito-
chondrial energy metabolism.
In view of the triad of (1) a severe progressive encepha-
lopathy, (2) associated with bilateral basal ganglia lesions
in MRI and autopsy, and (3) the mitochondrial dysfunc-
tion, ECHS1 deficiency is a new Leigh-like syndrome but
can be differentiated from other forms of Leigh syndrome
clinically and biochemically.
Analysis of OXPHOS enzymes in muscle
tissue and fibroblasts
Since the clinical presentation suggested a mitochondrial
disorder, eight of 10 patients received muscle and/or skin
biopsies with detailed analysis of respiratory chain com-
plexes, pyruvate dehydrogenase complex, ATP produc-
tion, and pyruvate oxidation. Despite the severe clinical
presentation of ECHS1 patients, only four of them
showed mild and inconsistent changes in pyruvate oxida-
tion (patient #42031), ATP production (patient #68761),
and decreased activities of NADH:CoQ oxidoreductase
(complex I of the respiratory chain) or cytochrome c oxi-
dase (complex IV of the respiratory chain). Noteworthy,
all these patients died (age of death: 4 months,
11 months, 3 years, 7.5 years), whereas four patients
without documented changes in these analyses (#52236,
#57277, #73663, #76656) have survived until now (age at
latest visit: 2, 5, 16, and 31 years of life).
Discussion
ECHS1 is a mitochondrial matrix enzyme that is involved
in several metabolic pathways including fatty acids and
amino acids. Deficiency of this enzyme is expected to
result in impaired mitochondrial fatty acid oxidation.
However, as the membrane-bound enzymatic machinery
of long-chain fatty acids remains intact, ketogenesis
should not be completely disrupted in ECHS1-deficient
individuals and, assumingly, the resulting clinical pheno-
type should be relatively benign – similar to SCAD defi-
ciency.18,19 In fact, ECHS1-deficient individuals showed
mild to moderate hypoketosis, but did neither present
with hypoketotic hypoglycemia and hypoglycemic enceph-
alopathy nor were acylcarnitine profiles in blood sugges-
tive of a mitochondrial b-oxidation disorder. Deficiency
of short-chain fatty acid oxidation, however, was
unmasked by palmitate loading of ECHS1-deficient fibro-
blasts (Fig. 4C). This metabolic challenge induced a selec-
tive increase in butyrylcarnitine in three of four patients
tested, which in combination with slightly increased ethyl-
malonate in urine reflects impaired oxidation of short-
chain fatty acids.
Despite this relatively mild metabolic derangement
(concerning mitochondrial b-oxidation), ECHS1-deficient
individuals presented with a severe clinical phenotype,
with a high frequency of Leigh-like syndrome, neonatal
lactic acidosis, sensorineural hearing loss, muscular hypo-
tonia, cardiomyopathy, and respiratory failure. Although
this combination of clinical findings, in particular the
leading neurological presentation, is rather uncommon
for fatty oxidation defects,20,21 there is some clinical over-
lap with long-chain acyl-CoA dehydrogenase (LCHAD)
deficiency and mitochondrial trifunctional protein (MTP)
deficiency which resemble a primary OXPHOS deficiency.
Affected individuals with LCHAD and MTP deficiency
show a high frequency of neurological signs and symp-
toms including developmental delay, muscular hypotonia,
epilepsy, and lipid storage myopathy as well as cardiomy-
opathy and sudden death in newborns and infants.22,23
Similar to ECHS1 deficiency, elevated lactate is also often
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found in LCHAD/MTP deficiency suggesting mitochon-
drial dysfunction.22,23 In contrast to ECHS1 deficiency,
however, individuals with LCHAD/MTP deficiency often
present with hepatic dysfunction, retinopathy and periph-
eral neuropathy, but usually lack dystonia and sensorineu-
ral hearing loss. Interestingly, accumulating long-chain
fatty acids and acyl-CoA are thought to act as mitochon-
drial toxins inhibiting energy metabolism in individuals
with LCHAD and MTP deficiency.24,25
The striking discrepancy between an expected moderate
impairment of mitochondrial fatty acid oxidation and the
severe clinical presentation of ECHS1-deficient individuals
argues for an additional pathomechanism. In addition to
its function in fatty acid oxidation, ECHS1 has also been
suggested to be involved in the L-isoleucine, L-valine and
L-lysine oxidation using tiglyl-CoA, 2-methacrylyl-CoA or
crotonyl-CoA, respectively, as a substrate (Fig. 1).26 2-
Methacrylyl-CoA is a highly reactive compound and read-
ily undergoes reactions with free sulfhydryl groups thereby
inactivating important sulfhydryl-containing enzymes such
as respiratory chain complexes and pyruvate dehydroge-
nase complex.26 Accumulation of 2-methacrylyl-CoA has
been considered as toxic compound in HIBCH deficiency,
a disorder of the fifth step of valine oxidation with Leigh-
like neurological phenotype and combined deficiency of
multiple mitochondrial enzymes (Fig. 1).4,5 The neurologi-
cal phenotypes of individuals with ECHS1 deficiency and
HIBCH deficiency are strikingly similar. As ECHS1 is sug-
gested to catalyze the fourth step of valine oxidation, accu-
mulation of 2-methacrylyl-CoA is expected and may be
responsible for some of the pathological changes. Indeed,
very recently, ECHS1 mutations were reported in two sib-
lings with Leigh disease and remarkable clinical and bio-
chemical similarities to HIBCH deficiency,6 with most
prominent elevations of methacrylate and acrylate metabo-
lites indicating deficiency of valine oxidation. Our observa-
tion of elevated levels of 2-methyl-2,3-dihydroxybutyrate
in the urinary organic acids, a likely derivative of valine
oxidation metabolites, provides further evidence for the
involvement of defective valine metabolism in the patho-
genesis of the disease. It may, in addition, be a useful bio-
marker of disease course as we observed some correlation
already with the disease severity. Despite the clinical and
biochemical similarities between ECHS1 and HIBCH defi-
ciency, patients with ECHS1 deficiency showed less often
impaired oxidative phosphorylation than those with HIB-
CH deficiency in the investigated fibroblasts or muscle
biopsy samples. However, those ECHS1 patients with
detectable OXPHOS deficiency had a severe course of dis-
ease and died during infancy or early childhood.
In conclusion, the identification of 10 unrelated indi-
viduals with ECHS1 mutations allowed us to define the
phenotypic spectrum of this new mitochondrial disease
entity which can be differentiated clinically and biochemi-
cally from other molecular causes of Leigh or Leigh-like
syndrome. Regarding pathogenesis, we found both a b-
oxidation defect and impaired valine oxidation. We
speculate that both defects contribute to the clinical and
biochemical phenotype of this newly defined disorder.
Intriguingly, ECHS1 deficiency may be amenable to
treatment, provided that the elevation of toxic 2-enoyl-
CoA compounds can be influenced by dietary intake. All
possibly affected amino acids (valine, isoleucine, and
lysine) in ECHS1 deficiency are essential amino acids and
their dietary uptake can be expected to influence their
catabolism. In addition, maintenance of high glucose lev-
els, as recommended in fatty acid oxidation defects might
be protective for the heart in ECHS1 deficiency. Anyway,
further studies – preferably with an ECHS1 animal model
– are necessary to unravel the exact pathomechanisms in
ECHS1 deficiency and the efficacy and safety of possible
treatments.
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